Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey.

ABSTRACT:

Objective

Early iatrogenic menopause in gynecological cancer survivors and BRCA mutation (BRCAm) carriers undergoing risk-reducing salpingo-oophorectomy (RRSO) is a major health concern. Hormone replacement therapy (HRT) is the most effective remedy, but remains underused in clinical practice. The Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) group promoted a national survey to investigate the knowledge and attitudes of healthcare professionals regarding the prescription of HRT.

Methods

The survey consisted of a self-administered, multiple-choice 45-item questionnaire, available online to all MITO members for 2 months starting from January 2022.

Results

A total of 61 participants completed the questionnaire (47 out of 180 MITO center

SUBMITTER: Palaia I 

PROVIDER: S-EPMC11107284 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature